Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market

Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market

After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However, this downturn will be short-lived and the market will regain growth from 2009 to $6.9 billion in 2017 driven by the launch of new treatments across the 7MM.

Scope

*This report gives a strategic analysis of the likely impact that recent events will have on the future insomnia market

*Includes insomnia-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

*This report provides a global market snapshot by including insomnia-specific sales analysis for leading brands outside the seven major markets

*Key conclusions are supported by key opinion leader comment

Highlights

During 2007, US sales of Ambien CR overtook sales of Lunesta indicating that Sanofi-Aventis' attempt to switch patients from Ambien to Ambien CR has been successful. Ambien CR is forecast to become the market leader in 2017, achieving sales of over $1.5 billion.

Actelion's orexin receptor antagonistalmorexantis forecast to be the main driver of pipeline sales products, contributing blockbuster revenues by 2017. This is higher than previous forecasts due to Actelion's recent commercialization deal with GlaxoSmithKline, which will enable the realization of almorexant's full commercial potential

Neurim and Lundbeck's Circadin (controlled release melatonin) is the most recent entry to the insomnia market in Germany and it is expected that the drug will be rolled out in remaining EU countries later in 2008. Due to an uncompetitive clinical profile Datamonitor forecasts sales of Circadin to be small compared to other leading brands

Reasons to Purchase

*Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2007 to 2017

*Quantify the current size of the seven major markets and the trends in the rest of the world

*Assess the impact of events, such as patent expiries and new product launches, on the insomnia-specific sales of key brand name products

20-Aug-08 PDF & DataPack Pages: 148

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions